We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App





Nucleic-Acid Based COVID-19 Vaccine Candidate Generates Immune Responses in 94% of Phase 1 Trial Participants

By HospiMedica International staff writers
Posted on 01 Jul 2020
Print article
Illustration
Illustration
INOVIO Pharmaceuticals, Inc. (Plymouth Meeting, PA, USA) has announced positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase 1 clinical trial cohorts.

One key feature of INOVIO's DNA vaccines is the ability to generate balanced antibody and T cell immune responses, which in the case of SARS-CoV-2 infection could be important in the development of potential COVID-19 vaccines. In this regard, recent scientific reports have highlighted that SARS-CoV-2-specific T cells found in convalescent patients have been positively implicated in controlling the severity of their COVID-19 disease while other studies have shown that a significant proportion (33% to 40%) of convalescent individuals in their reports had neutralizing antibody below detectable levels.

In the Phase 1 clinical trial of INO-4800, the company initially enrolled 40 healthy adult volunteers 18 to 50 years of age into 1.0 mg and 2.0 mg dose cohorts, with each participant receiving two doses of INO-4800 four weeks apart. Each dose was administered by intradermal injection using INOVIO's CELLECTRA 2000 device. INO-4800 was generally safe and well-tolerated in all participants in both cohorts through week 8; all ten reported adverse events (AEs) were grade 1 in severity, and most were local injection site redness. There were no reported serious adverse events (SAEs). Multiple immunology assays including those for humoral and cellular immune responses are being conducted for both 1.0 mg and 2.0 mg dose cohorts after two doses at week 6. Analyses to date have shown that 94% (34 out of 36 total trial participants) demonstrated overall immunological response rates based on preliminary data assessing humoral (binding and neutralizing) and T cell immune responses. In addition to positive interim Phase 1 data, INO-4800 has been shown to protect mice in SARS-CoV-2 viral challenge studies, where vaccination with INO-4800 prevented viral replication in the lungs of animals challenged with SARS-CoV-2.

Moreover, INO-4800 has been selected to participate in a non-human primate (NHP) challenge study as part of the US government's Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021. Additionally, INOVIO has expanded its Phase 1 trial to add older participants in additional cohorts and plans to initiate a Phase 2/3 efficacy trial this summer upon regulatory concurrence.

“We are very encouraged by the positive interim safety and preliminary cellular and humoral immune response results to date as well as the inclusion of INO-4800 in Operation Warp Speed,” said Dr. J. Joseph Kim, President and CEO of INOVIO. “We are also pleased that INO-4800 vaccination abrogated viral replication in the lungs of mice challenged with SARS-CoV-2. We look forward to urgently advancing INO-4800, as it is the only nucleic-acid based vaccine that is stable at room temperature for more than a year and does not require to be frozen in transport or for years of storage, which are important factors when implementing mass immunizations to battle the current pandemic.”

Related Links:
INOVIO Pharmaceuticals, Inc.

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
LED Examination Lamp
Clarity 50 LED
New
Mattress Replacement System
Carilex DualPlus

Print article

Channels

Critical Care

view channel
Image: This handheld scanner is moved over breast tissue to monitor how well breast cancer tumors respond to chemotherapy or radiation treatment (Photo courtesy of Boston University)

Novel Medical Device Inventions Use Light to Monitor Blood Pressure and Track Cancer Treatment Progress

Traditional blood pressure devices often leave room for human error. To address this, scientists at Boston University (Boston, MA, USA) have developed a new blood pressure monitoring device based on speckle... Read more

Surgical Techniques

view channel
Image: The new treatment combination for subdural hematoma reduces the risk of recurrence (Photo courtesy of Neurosurgery 85(6):801-807, December 2019)

Novel Combination of Surgery and Embolization for Subdural Hematoma Reduces Risk of Recurrence

Subdural hematomas, which occur when bleeding happens between the brain and its protective membrane due to trauma, are common in older adults. By 2030, chronic subdural hematomas are expected to become... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.